Contents

Volume 2, Issue 6 June 2020

Contents
Volume 2, Issue 6 June 2020
COLUMNS
COVID-19 AND BRAIN HEALTH …….……………………………….……….……………………..4
Global pandemic takes a toll on our brain health: how unexpected uncertainty makes you vulnerable to paranoia
https://doi.org/10.37756/bk.20.2.6.1
COVID-19 AND ANTIBODIES ………………….………………….………………..………………..10
Neutralizing antibodies: Viable treatment modality for COVID-19
https://doi.org/10.37756/bk.20.2.6.2
BIOTECH R&D AND INNOVATION NEWS…………………………………….……………….…17
Editor’s PICKS: Biotechnology Advances around the World
Malaria and Vaccines………………………………..…………………………………….…………18
Parkinson’ Disease……………………….…..….………………….…………………………………19
Agriculture and Food Science ……….……….…………………….…….……….………………20
COVID-19 and Blood Clots ………………………………..……………………………………….21
BIOTECH AND PHARMA INDUSTRY ROUNDUP..……………………………………….……..22
COVID-19 vaccine by Pfizer and BioNTech’s shows positive data …..…………..……..….22
A $900 million collaboration between Takeda and Carmine………………………………….22
A New H1N1 Strain can trigger another global pandemic…………………………..…….….22
FDA approves Pfizer and Merck KGaA’s Bavencio ……………………………………………22

ZILXI™ (minocycline), receives FDA approval for rosacea…………………………………..23
Price set for COVID-19 drug remdesivir…………………………………………………….……23
Meningococcal Vaccines expected to touch USD 9 billion by 2026 ………………………..23
Novartis partners with Eye & Ear hospital to manufacture coronavirus vaccine…………24
WHO plan to deliver 2 billion coronavirus vaccine doses…………………………………….24
Large scale phase 2 & 3 trials are underway for coronavirus vaccine……………………..24
Investments to counter Cancer genes…………………………………..…………………………24
Roche presents biomarker for cancer.……………………………..……………………..………25
HALIX B.V. to produce vaccines against COVID-19…………………………………………….25
SARS-CoV2 antibody tests might not be suitable for individual diagnosis………………..25
FDA rejects AbbVie’s eye drug…………………………………………………………………….25
EC pledges €4.9bn to grant access to medicines………………………………………………25
No beneficial effect of lopinavir-ritonavir on COVID-19 patients ……………….…………..25